Possible Vaccine Adverse Events,Source Title,Source Author,Source Date,Source Additional Information,Source URL
1p36 deletion syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
2-Hydroxyglutaric aciduria,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
5'nucleotidase increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Acoustic neuritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Acquired C1 inhibitor deficiency,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Acquired epidermolysis bullosa,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Acquired epileptic aphasia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Acute cutaneous lupus erythematosus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Acute disseminated encephalomyelitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
"Acute encephalitis with refractory, repetitive partial seizures",5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Acute febrile neutrophilic dermatosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Acute flaccid myelitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Acute haemorrhagic leukoencephalitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Acute haemorrhagic oedema of infancy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Acute kidney injury,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Acute macular outer retinopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Acute motor axonal neuropathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Acute motor-sensory axonal neuropathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Acute myocardial infarction,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Acute respiratory distress syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Acute respiratory failure,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Addison's disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Administration site thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Administration site vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Adrenal thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Adverse event following immunisation,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Ageusia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Agranulocytosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Air embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Alanine aminotransferase abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Alanine aminotransferase increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Alcoholic seizure,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Allergic bronchopulmonary mycosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Allergic oedema,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Alloimmune hepatitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Alopecia areata,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Alpers disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Alveolar proteinosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Ammonia abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Ammonia increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Amniotic cavity infection,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Amygdalohippocampectomy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Amyloid arthropathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Amyloidosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Amyloidosis senile,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anaphylactic reaction,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anaphylactic shock,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anaphylactic transfusion reaction,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anaphylactoid reaction,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anaphylactoid shock,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anaphylactoid syndrome of pregnancy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Angioedema,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Angiopathic neuropathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Ankylosing spondylitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anosmia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Antiacetylcholine receptor antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-actin antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-aquaporin-4 antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-basal ganglia antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-cyclic citrullinated peptide antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-epithelial antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-erythrocyte antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-exosome complex antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-GAD antibody negative,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-GAD antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-ganglioside antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Antigliadin antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-glomerular basement membrane antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-glomerular basement membrane disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-glycyl-tRNA synthetase antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-HLA antibody test positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-IA2 antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-insulin antibody increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-insulin antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-insulin receptor antibody increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-insulin receptor antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-interferon antibody negative,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-interferon antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-islet cell antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Antimitochondrial antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-muscle specific kinase antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-myelin-associated glycoprotein antibodies positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-myelin-associated glycoprotein associated polyneuropathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Antimyocardial antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-neuronal antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Antineutrophil cytoplasmic antibody increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Antineutrophil cytoplasmic antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-neutrophil cytoplasmic antibody positive vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-NMDA antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Antinuclear antibody increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Antinuclear antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Antiphospholipid antibodies positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Antiphospholipid syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-platelet antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-prothrombin antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Antiribosomal P antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-RNA polymerase III antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-saccharomyces cerevisiae antibody test positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-sperm antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-SRP antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Antisynthetase syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-thyroid antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-transglutaminase antibody increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-VGCC antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-VGKC antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-vimentin antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Antiviral prophylaxis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Antiviral treatment,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Anti-zinc transporter 8 antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Aortic embolus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Aortic thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Aortitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Aplasia pure red cell,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Aplastic anaemia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Application site thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Application site vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Arrhythmia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Arterial bypass occlusion,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Arterial bypass thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Arterial thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Arteriovenous fistula thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Arteriovenous graft site stenosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Arteriovenous graft thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Arteritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Arteritis coronary,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Arthralgia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Arthritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Arthritis enteropathic,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Ascites,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Aseptic cavernous sinus thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Aspartate aminotransferase abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Aspartate aminotransferase increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Aspartate-glutamate-transporter deficiency,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
AST to platelet ratio index increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
AST/ALT ratio abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Asthma,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Asymptomatic COVID-19,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Ataxia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Atheroembolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Atonic seizures,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Atrial thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Atrophic thyroiditis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Atypical benign partial epilepsy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Atypical pneumonia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Aura,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoantibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune anaemia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune aplastic anaemia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune arthritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune blistering disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune cholangitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune colitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune demyelinating disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune dermatitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune disorder,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune encephalopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune endocrine disorder,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune enteropathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune eye disorder,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune haemolytic anaemia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune heparin-induced thrombocytopenia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune hepatitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune hyperlipidaemia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune hypothyroidism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune inner ear disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune lung disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune lymphoproliferative syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune myocarditis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune myositis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune nephritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune neuropathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune neutropenia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune pancreatitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune pancytopenia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune pericarditis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune retinopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune thyroid disorder,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune thyroiditis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoimmune uveitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoinflammation with infantile enterocolitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autoinflammatory disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Automatism epileptic,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autonomic nervous system imbalance,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Autonomic seizure,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Axial spondyloarthritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Axillary vein thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Axonal and demyelinating polyneuropathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Axonal neuropathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Bacterascites,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Baltic myoclonic epilepsy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Band sensation,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Basedow's disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Basilar artery thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Basophilopenia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
B-cell aplasia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Behcet's syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Benign ethnic neutropenia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Benign familial neonatal convulsions,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Benign familial pemphigus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Benign rolandic epilepsy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Beta-2 glycoprotein antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Bickerstaff's encephalitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Bile output abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Bile output decreased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Biliary ascites,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Bilirubin conjugated abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Bilirubin conjugated increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Bilirubin urine present,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Biopsy liver abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Biotinidase deficiency,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Birdshot chorioretinopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Blood alkaline phosphatase abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Blood alkaline phosphatase increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Blood bilirubin abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Blood bilirubin increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Blood bilirubin unconjugated increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Blood cholinesterase abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Blood cholinesterase decreased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Blood pressure decreased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Blood pressure diastolic decreased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Blood pressure systolic decreased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Blue toe syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Brachiocephalic vein thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Brain stem embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Brain stem thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Bromosulphthalein test abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Bronchial oedema,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Bronchitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Bronchitis mycoplasmal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Bronchitis viral,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Bronchopulmonary aspergillosis allergic,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Bronchospasm,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Budd-Chiari syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Bulbar palsy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Butterfly rash,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
C1q nephropathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Caesarean section,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Calcium embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Capillaritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Caplan's syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cardiac amyloidosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cardiac arrest,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cardiac failure,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cardiac failure acute,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cardiac sarcoidosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cardiac ventricular thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cardiogenic shock,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cardiolipin antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cardiopulmonary failure,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cardio-respiratory arrest,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cardio-respiratory distress,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cardiovascular insufficiency,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Carotid arterial embolus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Carotid artery thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cataplexy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Catheter site thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Catheter site vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cavernous sinus thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
CDKL5 deficiency disorder,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
CEC syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cement embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Central nervous system lupus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Central nervous system vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cerebellar artery thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cerebellar embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cerebral amyloid angiopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cerebral arteritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cerebral artery embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cerebral artery thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cerebral gas embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cerebral microembolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cerebral septic infarct,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cerebral thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cerebral venous sinus thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cerebral venous thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cerebrospinal thrombotic tamponade,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cerebrovascular accident,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Change in seizure presentation,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Chest discomfort,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Child-Pugh-Turcotte score abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Child-Pugh-Turcotte score increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Chillblains,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Choking,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Choking sensation,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cholangitis sclerosing,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Chronic autoimmune glomerulonephritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Chronic cutaneous lupus erythematosus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Chronic fatigue syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Chronic gastritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Chronic inflammatory demyelinating polyradiculoneuropathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Chronic recurrent multifocal osteomyelitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Chronic respiratory failure,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Chronic spontaneous urticaria,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Circulatory collapse,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Circumoral oedema,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Circumoral swelling,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Clinically isolated syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Clonic convulsion,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Coeliac disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cogan's syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cold agglutinins positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cold type haemolytic anaemia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Colitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Colitis erosive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Colitis herpes,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Colitis microscopic,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Colitis ulcerative,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Collagen disorder,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Collagen-vascular disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Complement factor abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Complement factor C1 decreased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Complement factor C2 decreased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Complement factor C3 decreased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Complement factor C4 decreased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Complement factor decreased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Computerised tomogram liver abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Concentric sclerosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Congenital anomaly,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Congenital bilateral perisylvian syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Congenital herpes simplex infection,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Congenital myasthenic syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Congenital varicella infection,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Congestive hepatopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Convulsion in childhood,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Convulsions local,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Convulsive threshold lowered,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Coombs positive haemolytic anaemia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Coronary artery disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Coronary artery embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Coronary artery thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Coronary bypass thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Coronavirus infection,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Coronavirus test,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Coronavirus test negative,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Coronavirus test positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Corpus callosotomy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cough,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cough variant asthma,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
COVID-19,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
COVID-19 immunisation,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
COVID-19 pneumonia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
COVID-19 prophylaxis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
COVID-19 treatment,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cranial nerve disorder,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cranial nerve palsies multiple,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cranial nerve paralysis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
CREST syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Crohn's disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cryofibrinogenaemia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cryoglobulinaemia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
CSF oligoclonal band present,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
CSWS syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cutaneous amyloidosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cutaneous lupus erythematosus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cutaneous sarcoidosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cutaneous vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cyanosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cyclic neutropenia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cystitis interstitial,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cytokine release syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Cytokine storm,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
De novo purine synthesis inhibitors associated acute inflammatory syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Death neonatal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Deep vein thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Deep vein thrombosis postoperative,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Deficiency of bile secretion,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Deja vu,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Demyelinating polyneuropathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Demyelination,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Dermatitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Dermatitis bullous,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Dermatitis herpetiformis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Dermatomyositis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Device embolisation,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Device related thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Diabetes mellitus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Diabetic ketoacidosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Diabetic mastopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Dialysis amyloidosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Dialysis membrane reaction,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Diastolic hypotension,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Diffuse vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Digital pitting scar,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Disseminated intravascular coagulation,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Disseminated intravascular coagulation in newborn,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Disseminated neonatal herpes simplex,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Disseminated varicella,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Disseminated varicella zoster vaccine virus infection,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Disseminated varicella zoster virus infection,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
DNA antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Double cortex syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Double stranded DNA antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Dreamy state,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Dressler's syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Drop attacks,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Drug withdrawal convulsions,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Dyspnoea,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Early infantile epileptic encephalopathy with burst-suppression,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Eclampsia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Eczema herpeticum,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Embolia cutis medicamentosa,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Embolic cerebellar infarction,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Embolic cerebral infarction,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Embolic pneumonia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Embolic stroke,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Embolism arterial,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Embolism venous,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Encephalitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Encephalitis allergic,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Encephalitis autoimmune,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Encephalitis brain stem,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Encephalitis haemorrhagic,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Encephalitis periaxialis diffusa,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Encephalitis post immunisation,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Encephalomyelitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Encephalopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Endocrine disorder,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Endocrine ophthalmopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Endotracheal intubation,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Enteritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Enteritis leukopenic,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Enterobacter pneumonia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Enterocolitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Enteropathic spondylitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Eosinopenia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Eosinophilic fasciitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Eosinophilic granulomatosis with polyangiitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Eosinophilic oesophagitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Epidermolysis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Epilepsy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Epilepsy surgery,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Epilepsy with myoclonic-atonic seizures,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Epileptic aura,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Epileptic psychosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Erythema,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Erythema induratum,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Erythema multiforme,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Erythema nodosum,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Evans syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Exanthema subitum,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Expanded disability status scale score decreased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Expanded disability status scale score increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Exposure to communicable disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Exposure to SARS-CoV-2,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Eye oedema,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Eye pruritus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Eye swelling,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Eyelid oedema,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Face oedema,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Facial paralysis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Facial paresis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Faciobrachial dystonic seizure,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Fat embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Febrile convulsion,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Febrile infection-related epilepsy syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Febrile neutropenia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Felty's syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Femoral artery embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Fibrillary glomerulonephritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Fibromyalgia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Flushing,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Foaming at mouth,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Focal cortical resection,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Focal dyscognitive seizures,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Foetal distress syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Foetal placental thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Foetor hepaticus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Foreign body embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Frontal lobe epilepsy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Fulminant type 1 diabetes mellitus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Galactose elimination capacity test abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Galactose elimination capacity test decreased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Gamma-glutamyltransferase abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Gamma-glutamyltransferase increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Gastritis herpes,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Gastrointestinal amyloidosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Gelastic seizure,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Generalised onset non-motor seizure,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Generalised tonic-clonic seizure,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Genital herpes,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Genital herpes simplex,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Genital herpes zoster,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Giant cell arteritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Glomerulonephritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Glomerulonephritis membranoproliferative,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Glomerulonephritis membranous,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Glomerulonephritis rapidly progressive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Glossopharyngeal nerve paralysis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Glucose transporter type 1 deficiency syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Glutamate dehydrogenase increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Glycocholic acid increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
GM2 gangliosidosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Goodpasture's syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Graft thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Granulocytopenia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Granulocytopenia neonatal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Granulomatosis with polyangiitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Granulomatous dermatitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Grey matter heterotopia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Guanase increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Guillain-Barre syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Haemolytic anaemia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Haemophagocytic lymphohistiocytosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Haemorrhage,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Haemorrhagic ascites,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Haemorrhagic disorder,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Haemorrhagic pneumonia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Haemorrhagic varicella syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Haemorrhagic vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hantavirus pulmonary infection,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hashimoto's encephalopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hashitoxicosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hemimegalencephaly,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Henoch-Schonlein purpura,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Henoch-Schonlein purpura nephritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepaplastin abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepaplastin decreased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Heparin-induced thrombocytopenia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic amyloidosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic artery embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic artery flow decreased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic artery thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic enzyme abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic enzyme decreased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic enzyme increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic fibrosis marker abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic fibrosis marker increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic function abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic hydrothorax,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic hypertrophy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic hypoperfusion,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic lymphocytic infiltration,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic mass,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic pain,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic sequestration,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic vascular resistance increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic vascular thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic vein embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic vein thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic venous pressure gradient abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatic venous pressure gradient increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatobiliary scan abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatomegaly,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hepatosplenomegaly,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hereditary angioedema with C1 esterase inhibitor deficiency,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes dermatitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes gestationis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes oesophagitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes ophthalmic,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes pharyngitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes sepsis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes simplex,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes simplex cervicitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes simplex colitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes simplex encephalitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes simplex gastritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes simplex hepatitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes simplex meningitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes simplex meningoencephalitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes simplex meningomyelitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes simplex necrotising retinopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes simplex oesophagitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes simplex otitis externa,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes simplex pharyngitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes simplex pneumonia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes simplex reactivation,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes simplex sepsis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes simplex viraemia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes simplex virus conjunctivitis neonatal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes simplex visceral,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes virus infection,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes zoster,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes zoster cutaneous disseminated,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes zoster infection neurological,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes zoster meningitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes zoster meningoencephalitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes zoster meningomyelitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes zoster meningoradiculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes zoster necrotising retinopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes zoster oticus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes zoster pharyngitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpes zoster reactivation,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Herpetic radiculopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Histone antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hoigne's syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Human herpesvirus 6 encephalitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Human herpesvirus 6 infection,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Human herpesvirus 6 infection reactivation,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Human herpesvirus 7 infection,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Human herpesvirus 8 infection,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hyperammonaemia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hyperbilirubinaemia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hypercholia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hypergammaglobulinaemia benign monoclonal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hyperglycaemic seizure,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hypersensitivity,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hypersensitivity vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hyperthyroidism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hypertransaminasaemia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hyperventilation,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hypoalbuminaemia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hypocalcaemic seizure,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hypogammaglobulinaemia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hypoglossal nerve paralysis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hypoglossal nerve paresis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hypoglycaemic seizure,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hyponatraemic seizure,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hypotension,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hypotensive crisis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hypothenar hammer syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hypothyroidism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Hypoxia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Idiopathic CD4 lymphocytopenia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Idiopathic generalised epilepsy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Idiopathic interstitial pneumonia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Idiopathic neutropenia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Idiopathic pulmonary fibrosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
IgA nephropathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
IgM nephropathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
IIIrd nerve paralysis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
IIIrd nerve paresis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Iliac artery embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune thrombocytopenia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune-mediated adverse reaction,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune-mediated cholangitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune-mediated cholestasis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune-mediated cytopenia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune-mediated encephalitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune-mediated encephalopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune-mediated endocrinopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune-mediated enterocolitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune-mediated gastritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune-mediated hepatic disorder,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune-mediated hepatitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune-mediated hyperthyroidism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune-mediated hypothyroidism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune-mediated myocarditis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune-mediated myositis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune-mediated nephritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune-mediated neuropathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune-mediated pancreatitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune-mediated pneumonitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune-mediated renal disorder,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune-mediated thyroiditis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immune-mediated uveitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immunoglobulin G4 related disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Immunoglobulins abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Implant site thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Inclusion body myositis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Infantile genetic agranulocytosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Infantile spasms,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Infected vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Infective thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Inflammation,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Inflammatory bowel disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Infusion site thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Infusion site vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Injection site thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Injection site urticaria,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Injection site vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Instillation site thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Insulin autoimmune syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Interstitial granulomatous dermatitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Interstitial lung disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Intracardiac mass,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Intracardiac thrombus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Intracranial pressure increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Intrapericardial thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Intrinsic factor antibody abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Intrinsic factor antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
IPEX syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Irregular breathing,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
IRVAN syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
IVth nerve paralysis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
IVth nerve paresis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
JC polyomavirus test positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
JC virus CSF test positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Jeavons syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Jugular vein embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Jugular vein thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Juvenile idiopathic arthritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Juvenile myoclonic epilepsy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Juvenile polymyositis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Juvenile psoriatic arthritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Juvenile spondyloarthritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Kaposi sarcoma inflammatory cytokine syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Kawasaki's disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Kayser-Fleischer ring,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Keratoderma blenorrhagica,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Ketosis-prone diabetes mellitus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Kounis syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lafora's myoclonic epilepsy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lambl's excrescences,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Laryngeal dyspnoea,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Laryngeal oedema,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Laryngeal rheumatoid arthritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Laryngospasm,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Laryngotracheal oedema,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Latent autoimmune diabetes in adults,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
LE cells present,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lemierre syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lennox-Gastaut syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Leucine aminopeptidase increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Leukoencephalomyelitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Leukoencephalopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Leukopenia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Leukopenia neonatal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lewis-Sumner syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lhermitte's sign,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lichen planopilaris,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lichen planus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lichen sclerosus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Limbic encephalitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Linear IgA disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lip oedema,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lip swelling,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Liver function test abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Liver function test decreased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Liver function test increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Liver induration,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Liver injury,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Liver iron concentration abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Liver iron concentration increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Liver opacity,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Liver palpable,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Liver sarcoidosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Liver scan abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Liver tenderness,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Low birth weight baby,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lower respiratory tract herpes infection,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lower respiratory tract infection,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lower respiratory tract infection viral,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lung abscess,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lupoid hepatic cirrhosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lupus cystitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lupus encephalitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lupus endocarditis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lupus enteritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lupus hepatitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lupus myocarditis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lupus myositis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lupus nephritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lupus pancreatitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lupus pleurisy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lupus pneumonitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lupus vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lupus-like syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lymphocytic hypophysitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lymphocytopenia neonatal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Lymphopenia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
MAGIC syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Magnetic resonance imaging liver abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Magnetic resonance proton density fat fraction measurement,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Mahler sign,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Manufacturing laboratory analytical testing issue,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Manufacturing materials issue,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Manufacturing production issue,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Marburg's variant multiple sclerosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Marchiafava-Bignami disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Marine Lenhart syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Mastocytic enterocolitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Maternal exposure during pregnancy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Medical device site thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Medical device site vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
MELAS syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Meningitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Meningitis aseptic,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Meningitis herpes,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Meningoencephalitis herpes simplex neonatal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Meningoencephalitis herpetic,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Meningomyelitis herpes,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
MERS-CoV test,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
MERS-CoV test negative,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
MERS-CoV test positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Mesangioproliferative glomerulonephritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Mesenteric artery embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Mesenteric artery thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Mesenteric vein thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Metapneumovirus infection,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Metastatic cutaneous Crohn's disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Metastatic pulmonary embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Microangiopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Microembolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Microscopic polyangiitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Middle East respiratory syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Migraine-triggered seizure,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Miliary pneumonia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Miller Fisher syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Mitochondrial aspartate aminotransferase increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Mixed connective tissue disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Model for end stage liver disease score abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Model for end stage liver disease score increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Molar ratio of total branched-chain amino acid to tyrosine,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Molybdenum cofactor deficiency,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Monocytopenia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Mononeuritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Mononeuropathy multiplex,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Morphoea,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Morvan syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Mouth swelling,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Moyamoya disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Multifocal motor neuropathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Multiple organ dysfunction syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Multiple sclerosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Multiple sclerosis relapse,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Multiple sclerosis relapse prophylaxis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Multiple subpial transection,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Multisystem inflammatory syndrome in children,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Muscular sarcoidosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Myasthenia gravis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Myasthenia gravis crisis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Myasthenia gravis neonatal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Myasthenic syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Myelitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Myelitis transverse,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Myocardial infarction,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Myocarditis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Myocarditis post infection,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Myoclonic epilepsy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Myoclonic epilepsy and ragged-red fibres,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Myokymia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Myositis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Narcolepsy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Nasal herpes,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Nasal obstruction,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Necrotising herpetic retinopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Neonatal Crohn's disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Neonatal epileptic seizure,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Neonatal lupus erythematosus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Neonatal mucocutaneous herpes simplex,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Neonatal pneumonia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Neonatal seizure,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Nephritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Nephrogenic systemic fibrosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Neuralgic amyotrophy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Neuritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Neuritis cranial,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Neuromyelitis optica pseudo relapse,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Neuromyelitis optica spectrum disorder,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Neuromyotonia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Neuronal neuropathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Neuropathy peripheral,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
"Neuropathy, ataxia, retinitis pigmentosa syndrome",5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Neuropsychiatric lupus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Neurosarcoidosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Neutropenia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Neutropenia neonatal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Neutropenic colitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Neutropenic infection,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Neutropenic sepsis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Nodular rash,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Nodular vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Noninfectious myelitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Noninfective encephalitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Noninfective encephalomyelitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Noninfective oophoritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Obstetrical pulmonary embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Occupational exposure to communicable disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Occupational exposure to SARS-CoV-2,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Ocular hyperaemia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Ocular myasthenia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Ocular pemphigoid,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Ocular sarcoidosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Ocular vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Oculofacial paralysis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Oedema,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Oedema blister,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Oedema due to hepatic disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Oedema mouth,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Oesophageal achalasia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Ophthalmic artery thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Ophthalmic herpes simplex,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Ophthalmic herpes zoster,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Ophthalmic vein thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Optic neuritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Optic neuropathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Optic perineuritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Oral herpes,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Oral lichen planus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Oropharyngeal oedema,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Oropharyngeal spasm,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Oropharyngeal swelling,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Osmotic demyelination syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Ovarian vein thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Overlap syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Paget-Schroetter syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Palindromic rheumatism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Palisaded neutrophilic granulomatous dermatitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Palmoplantar keratoderma,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Palpable purpura,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pancreatitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Panencephalitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Papillophlebitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Paracancerous pneumonia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Paradoxical embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Parainfluenzae viral laryngotracheobronchitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Paraneoplastic dermatomyositis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Paraneoplastic pemphigus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Paraneoplastic thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Paresis cranial nerve,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Parietal cell antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Paroxysmal nocturnal haemoglobinuria,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Partial seizures,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Partial seizures with secondary generalisation,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Patient isolation,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pelvic venous thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pemphigoid,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pemphigus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Penile vein thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pericarditis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pericarditis lupus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Perihepatic discomfort,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Periorbital oedema,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Periorbital swelling,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Peripheral artery thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Peripheral embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Peripheral ischaemia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Peripheral vein thrombus extension,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Periportal oedema,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Peritoneal fluid protein abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Peritoneal fluid protein decreased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Peritoneal fluid protein increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Peritonitis lupus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pernicious anaemia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Petit mal epilepsy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pharyngeal oedema,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pharyngeal swelling,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pityriasis lichenoides et varioliformis acuta,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Placenta praevia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pleuroparenchymal fibroelastosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pneumobilia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pneumonia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pneumonia adenoviral,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pneumonia cytomegaloviral,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pneumonia herpes viral,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pneumonia influenzal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pneumonia measles,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pneumonia mycoplasmal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pneumonia necrotising,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pneumonia parainfluenzae viral,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pneumonia respiratory syncytial viral,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pneumonia viral,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
POEMS syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Polyarteritis nodosa,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Polyarthritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Polychondritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Polyglandular autoimmune syndrome type I,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Polyglandular autoimmune syndrome type II,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Polyglandular autoimmune syndrome type III,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Polyglandular disorder,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Polymicrogyria,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Polymyalgia rheumatica,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Polymyositis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Polyneuropathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Polyneuropathy idiopathic progressive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Portal pyaemia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Portal vein embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Portal vein flow decreased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Portal vein pressure increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Portal vein thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Portosplenomesenteric venous thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Post procedural hypotension,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Post procedural pneumonia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Post procedural pulmonary embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Post stroke epilepsy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Post stroke seizure,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Post thrombotic retinopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Post thrombotic syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Post viral fatigue syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Postictal headache,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Postictal paralysis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Postictal psychosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Postictal state,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Postoperative respiratory distress,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Postoperative respiratory failure,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Postoperative thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Postpartum thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Postpartum venous thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Postpericardiotomy syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Post-traumatic epilepsy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Postural orthostatic tachycardia syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Precerebral artery thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pre-eclampsia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Preictal state,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Premature labour,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Premature menopause,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Primary amyloidosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Primary biliary cholangitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Primary progressive multiple sclerosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Procedural shock,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Proctitis herpes,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Proctitis ulcerative,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Product availability issue,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Product distribution issue,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Product supply issue,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Progressive facial hemiatrophy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Progressive multifocal leukoencephalopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Progressive multiple sclerosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Progressive relapsing multiple sclerosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Prosthetic cardiac valve thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pruritus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pruritus allergic,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pseudovasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Psoriasis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Psoriatic arthropathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pulmonary amyloidosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pulmonary artery thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pulmonary embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pulmonary fibrosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pulmonary haemorrhage,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pulmonary microemboli,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pulmonary oil microembolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pulmonary renal syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pulmonary sarcoidosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pulmonary sepsis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pulmonary thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pulmonary tumour thrombotic microangiopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pulmonary vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pulmonary veno-occlusive disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pulmonary venous thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pyoderma gangrenosum,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pyostomatitis vegetans,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Pyrexia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Quarantine,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Radiation leukopenia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Radiculitis brachial,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Radiologically isolated syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Rash,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Rash erythematous,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Rash pruritic,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Rasmussen encephalitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Raynaud's phenomenon,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Reactive capillary endothelial proliferation,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Relapsing multiple sclerosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Relapsing-remitting multiple sclerosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Renal amyloidosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Renal arteritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Renal artery thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Renal embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Renal failure,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Renal vascular thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Renal vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Renal vein embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Renal vein thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Respiratory arrest,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Respiratory disorder,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Respiratory distress,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Respiratory failure,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Respiratory paralysis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Respiratory syncytial virus bronchiolitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Respiratory syncytial virus bronchitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Retinal artery embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Retinal artery occlusion,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Retinal artery thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Retinal vascular thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Retinal vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Retinal vein occlusion,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Retinal vein thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Retinol binding protein decreased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Retinopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Retrograde portal vein flow,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Retroperitoneal fibrosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Reversible airways obstruction,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Reynold's syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Rheumatic brain disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Rheumatic disorder,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Rheumatoid arthritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Rheumatoid factor increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Rheumatoid factor positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Rheumatoid factor quantitative increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Rheumatoid lung,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Rheumatoid neutrophilic dermatosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Rheumatoid nodule,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Rheumatoid nodule removal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Rheumatoid scleritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Rheumatoid vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Saccadic eye movement,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
SAPHO syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Sarcoidosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
SARS-CoV-1 test,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
SARS-CoV-1 test negative,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
SARS-CoV-1 test positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
SARS-CoV-2 antibody test,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
SARS-CoV-2 antibody test negative,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
SARS-CoV-2 antibody test positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
SARS-CoV-2 carrier,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
SARS-CoV-2 sepsis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
SARS-CoV-2 test,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
SARS-CoV-2 test false negative,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
SARS-CoV-2 test false positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
SARS-CoV-2 test negative,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
SARS-CoV-2 test positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
SARS-CoV-2 viraemia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Satoyoshi syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Schizencephaly,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Scleritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Sclerodactylia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Scleroderma,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Scleroderma associated digital ulcer,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Scleroderma renal crisis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Scleroderma-like reaction,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Secondary amyloidosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Secondary cerebellar degeneration,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Secondary progressive multiple sclerosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Segmented hyalinising vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Seizure,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Seizure anoxic,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Seizure cluster,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Seizure like phenomena,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Seizure prophylaxis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Sensation of foreign body,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Septic embolus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Septic pulmonary embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Severe acute respiratory syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Severe myoclonic epilepsy of infancy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Shock,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Shock symptom,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Shrinking lung syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Shunt thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Silent thyroiditis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Simple partial seizures,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Sjogren's syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Skin swelling,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
SLE arthritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Smooth muscle antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Sneezing,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Spinal artery embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Spinal artery thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Splenic artery thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Splenic embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Splenic thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Splenic vein thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Spondylitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Spondyloarthropathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Spontaneous heparin-induced thrombocytopenia syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Status epilepticus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Stevens-Johnson syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Stiff leg syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Stiff person syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Stillbirth,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Still's disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Stoma site thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Stoma site vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Stress cardiomyopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Stridor,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Subacute cutaneous lupus erythematosus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Subacute endocarditis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Subacute inflammatory demyelinating polyneuropathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Subclavian artery embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Subclavian artery thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Subclavian vein thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Sudden unexplained death in epilepsy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Superior sagittal sinus thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Susac's syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Suspected COVID-19,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Swelling,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Swelling face,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Swelling of eyelid,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Swollen tongue,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Sympathetic ophthalmia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Systemic lupus erythematosus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Systemic lupus erythematosus disease activity index abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Systemic lupus erythematosus disease activity index decreased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Systemic lupus erythematosus disease activity index increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Systemic lupus erythematosus rash,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Systemic scleroderma,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Systemic sclerosis pulmonary,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Tachycardia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Tachypnoea,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Takayasu's arteritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Temporal lobe epilepsy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Terminal ileitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Testicular autoimmunity,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Throat tightness,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Thromboangiitis obliterans,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Thrombocytopenia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Thrombocytopenic purpura,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Thrombophlebitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Thrombophlebitis migrans,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Thrombophlebitis neonatal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Thrombophlebitis septic,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Thrombophlebitis superficial,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Thromboplastin antibody positive,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Thrombosis corpora cavernosa,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Thrombosis in device,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Thrombosis mesenteric vessel,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Thrombotic cerebral infarction,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Thrombotic microangiopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Thrombotic stroke,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Thrombotic thrombocytopenic purpura,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Thyroid disorder,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Thyroid stimulating immunoglobulin increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Thyroiditis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Tongue amyloidosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Tongue biting,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Tongue oedema,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Tonic clonic movements,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Tonic convulsion,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Tonic posturing,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Topectomy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Total bile acids increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Toxic epidermal necrolysis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Toxic leukoencephalopathy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Toxic oil syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Tracheal obstruction,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Tracheal oedema,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Tracheobronchitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Tracheobronchitis mycoplasmal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Tracheobronchitis viral,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Transaminases abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Transaminases increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Transfusion-related alloimmune neutropenia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Transient epileptic amnesia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Transverse sinus thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Trigeminal nerve paresis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Trigeminal neuralgia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Trigeminal palsy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Truncus coeliacus thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Tuberous sclerosis complex,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Tubulointerstitial nephritis and uveitis syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Tumefactive multiple sclerosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Tumour embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Tumour thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Type 1 diabetes mellitus,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Type I hypersensitivity,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Type III immune complex mediated reaction,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Uhthoff's phenomenon,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Ulcerative keratitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Ultrasound liver abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Umbilical cord thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Uncinate fits,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Undifferentiated connective tissue disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Upper airway obstruction,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Urine bilirubin increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Urobilinogen urine decreased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Urobilinogen urine increased,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Urticaria,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Urticaria papular,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Urticarial vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Uterine rupture,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Uveitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Vaccination site thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Vaccination site vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Vagus nerve paralysis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Varicella,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Varicella keratitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Varicella post vaccine,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Varicella zoster gastritis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Varicella zoster oesophagitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Varicella zoster pneumonia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Varicella zoster sepsis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Varicella zoster virus infection,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Vasa praevia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Vascular graft thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Vascular pseudoaneurysm thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Vascular purpura,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Vascular stent thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Vasculitic rash,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Vasculitic ulcer,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Vasculitis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Vasculitis gastrointestinal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Vasculitis necrotising,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Vena cava embolism,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Vena cava thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Venous intravasation,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Venous recanalisation,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Venous thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Venous thrombosis in pregnancy,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Venous thrombosis limb,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Venous thrombosis neonatal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Vertebral artery thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Vessel puncture site thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Visceral venous thrombosis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
VIth nerve paralysis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
VIth nerve paresis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Vitiligo,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Vocal cord paralysis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Vocal cord paresis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Vogt-Koyanagi-Harada disease,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Warm type haemolytic anaemia,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Wheezing,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
White nipple sign,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
XIth nerve paralysis,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
X-ray hepatobiliary abnormal,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Young's syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Zika virus associated Guillain Barre syndrome,5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-Feb-2021 Report,Worldwide Safety Pfizer,2021-04-30,Document was released as part of a Freedom of Information Act (FOIA) lawsuit against the United States Food and Drug Administration (FDA) filed by the Public Health and Medical Professionals for Transparency non-profit organization,https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf
Adenopathy,Neuritis and Multiple Neuritis Following Serum Therapy,"George Wilson, M.D. and Samuel B. Hadden, M.D.",1932-01-09,"'JAMA's. 1932; 98(2), pages 123-125",https://jamanetwork.com/journals/jama/article-abstract/1153665
Anaphylaxis,Neuritis and Multiple Neuritis Following Serum Therapy,"George Wilson, M.D. and Samuel B. Hadden, M.D.",1932-01-09,"'JAMA's. 1932; 98(2), pages 123-125",https://jamanetwork.com/journals/jama/article-abstract/1153665
Arthralgia,Neuritis and Multiple Neuritis Following Serum Therapy,"George Wilson, M.D. and Samuel B. Hadden, M.D.",1932-01-09,"'JAMA's. 1932; 98(2), pages 123-125",https://jamanetwork.com/journals/jama/article-abstract/1153665
Cardiac collapse,Neuritis and Multiple Neuritis Following Serum Therapy,"George Wilson, M.D. and Samuel B. Hadden, M.D.",1932-01-09,"'JAMA's. 1932; 98(2), pages 123-125",https://jamanetwork.com/journals/jama/article-abstract/1153665
Coma,Neuritis and Multiple Neuritis Following Serum Therapy,"George Wilson, M.D. and Samuel B. Hadden, M.D.",1932-01-09,"'JAMA's. 1932; 98(2), pages 123-125",https://jamanetwork.com/journals/jama/article-abstract/1153665
Death,Neuritis and Multiple Neuritis Following Serum Therapy,"George Wilson, M.D. and Samuel B. Hadden, M.D.",1932-01-09,"'JAMA's. 1932; 98(2), pages 123-125",https://jamanetwork.com/journals/jama/article-abstract/1153665
Encephalitis,Neuritis and Multiple Neuritis Following Serum Therapy,"George Wilson, M.D. and Samuel B. Hadden, M.D.",1932-01-09,"'JAMA's. 1932; 98(2), pages 123-125",https://jamanetwork.com/journals/jama/article-abstract/1153665
Multiple neuritis,Neuritis and Multiple Neuritis Following Serum Therapy,"George Wilson, M.D. and Samuel B. Hadden, M.D.",1932-01-09,"'JAMA's. 1932; 98(2), pages 123-125",https://jamanetwork.com/journals/jama/article-abstract/1153665
Myelitis,Neuritis and Multiple Neuritis Following Serum Therapy,"George Wilson, M.D. and Samuel B. Hadden, M.D.",1932-01-09,"'JAMA's. 1932; 98(2), pages 123-125",https://jamanetwork.com/journals/jama/article-abstract/1153665
Paralysis of the serratus magnus and other muscles,Neuritis and Multiple Neuritis Following Serum Therapy,"George Wilson, M.D. and Samuel B. Hadden, M.D.",1932-01-09,"'JAMA's. 1932; 98(2), pages 123-125",https://jamanetwork.com/journals/jama/article-abstract/1153665
Urticaria,Neuritis and Multiple Neuritis Following Serum Therapy,"George Wilson, M.D. and Samuel B. Hadden, M.D.",1932-01-09,"'JAMA's. 1932; 98(2), pages 123-125",https://jamanetwork.com/journals/jama/article-abstract/1153665
Acute disseminated encephalomyelitis,"US Food and Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation","Steve Anderson, PhD, MPP",2020-10-22,page 17; Document was Recovered with the Internet Archive: Wayback Machine,https://web.archive.org/web/20201126033341/https://www.fda.gov/media/143557/download
Acute myocardial infarction,"US Food and Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation","Steve Anderson, PhD, MPP",2020-10-22,page 17; Document was Recovered with the Internet Archive: Wayback Machine,https://web.archive.org/web/20201126033341/https://www.fda.gov/media/143557/download
Anaphylaxis,"US Food and Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation","Steve Anderson, PhD, MPP",2020-10-22,page 17; Document was Recovered with the Internet Archive: Wayback Machine,https://web.archive.org/web/20201126033341/https://www.fda.gov/media/143557/download
Arthritis and arthralgia/joint pain,"US Food and Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation","Steve Anderson, PhD, MPP",2020-10-22,page 17; Document was Recovered with the Internet Archive: Wayback Machine,https://web.archive.org/web/20201126033341/https://www.fda.gov/media/143557/download
Autoimmune disease,"US Food and Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation","Steve Anderson, PhD, MPP",2020-10-22,page 17; Document was Recovered with the Internet Archive: Wayback Machine,https://web.archive.org/web/20201126033341/https://www.fda.gov/media/143557/download
Convulsions/seizures,"US Food and Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation","Steve Anderson, PhD, MPP",2020-10-22,page 17; Document was Recovered with the Internet Archive: Wayback Machine,https://web.archive.org/web/20201126033341/https://www.fda.gov/media/143557/download
Deaths,"US Food and Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation","Steve Anderson, PhD, MPP",2020-10-22,page 17; Document was Recovered with the Internet Archive: Wayback Machine,https://web.archive.org/web/20201126033341/https://www.fda.gov/media/143557/download
Disseminated intravascular coagulation,"US Food and Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation","Steve Anderson, PhD, MPP",2020-10-22,page 17; Document was Recovered with the Internet Archive: Wayback Machine,https://web.archive.org/web/20201126033341/https://www.fda.gov/media/143557/download
Encephalitis/myelitis/encephalomyelitis/meningoencephalitis/meningitis/encepholapathy,"US Food and Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation","Steve Anderson, PhD, MPP",2020-10-22,page 17; Document was Recovered with the Internet Archive: Wayback Machine,https://web.archive.org/web/20201126033341/https://www.fda.gov/media/143557/download
Guillain-Barré syndrome,"US Food and Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation","Steve Anderson, PhD, MPP",2020-10-22,page 17; Document was Recovered with the Internet Archive: Wayback Machine,https://web.archive.org/web/20201126033341/https://www.fda.gov/media/143557/download
Kawasaki disease,"US Food and Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation","Steve Anderson, PhD, MPP",2020-10-22,page 17; Document was Recovered with the Internet Archive: Wayback Machine,https://web.archive.org/web/20201126033341/https://www.fda.gov/media/143557/download
Multisystem Inflammatory Syndrome in Children,"US Food and Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation","Steve Anderson, PhD, MPP",2020-10-22,page 17; Document was Recovered with the Internet Archive: Wayback Machine,https://web.archive.org/web/20201126033341/https://www.fda.gov/media/143557/download
Myocarditis/pericarditis,"US Food and Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation","Steve Anderson, PhD, MPP",2020-10-22,page 17; Document was Recovered with the Internet Archive: Wayback Machine,https://web.archive.org/web/20201126033341/https://www.fda.gov/media/143557/download
Narcolepsy and cataplexy,"US Food and Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation","Steve Anderson, PhD, MPP",2020-10-22,page 17; Document was Recovered with the Internet Archive: Wayback Machine,https://web.archive.org/web/20201126033341/https://www.fda.gov/media/143557/download
Non-anaphylactic allergic reactions,"US Food and Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation","Steve Anderson, PhD, MPP",2020-10-22,page 17; Document was Recovered with the Internet Archive: Wayback Machine,https://web.archive.org/web/20201126033341/https://www.fda.gov/media/143557/download
Other acute demyelinating diseases,"US Food and Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation","Steve Anderson, PhD, MPP",2020-10-22,page 17; Document was Recovered with the Internet Archive: Wayback Machine,https://web.archive.org/web/20201126033341/https://www.fda.gov/media/143557/download
Pregnancy and birth outcomes,"US Food and Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation","Steve Anderson, PhD, MPP",2020-10-22,page 17; Document was Recovered with the Internet Archive: Wayback Machine,https://web.archive.org/web/20201126033341/https://www.fda.gov/media/143557/download
Stroke,"US Food and Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation","Steve Anderson, PhD, MPP",2020-10-22,page 17; Document was Recovered with the Internet Archive: Wayback Machine,https://web.archive.org/web/20201126033341/https://www.fda.gov/media/143557/download
Thrombocytopenia,"US Food and Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation","Steve Anderson, PhD, MPP",2020-10-22,page 17; Document was Recovered with the Internet Archive: Wayback Machine,https://web.archive.org/web/20201126033341/https://www.fda.gov/media/143557/download
Transverse myelitis,"US Food and Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation","Steve Anderson, PhD, MPP",2020-10-22,page 17; Document was Recovered with the Internet Archive: Wayback Machine,https://web.archive.org/web/20201126033341/https://www.fda.gov/media/143557/download
Vaccine enhanced disease,"US Food and Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation","Steve Anderson, PhD, MPP",2020-10-22,page 17; Document was Recovered with the Internet Archive: Wayback Machine,https://web.archive.org/web/20201126033341/https://www.fda.gov/media/143557/download
Venous thromboembolism,"US Food and Drug Administration (FDA): Vaccines and Related Biological Products Advisory Committee October 22, 2020 Meeting Presentation","Steve Anderson, PhD, MPP",2020-10-22,page 17; Document was Recovered with the Internet Archive: Wayback Machine,https://web.archive.org/web/20201126033341/https://www.fda.gov/media/143557/download
